14300EGP
- Active ingredient
- durvalumab
- Strength
- 120mg/2.4ml
- Form
- vial
- Manufacturer
- astra zeneca
- Route
- injection
Uses
Used in the treatment of several cancers including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and other approved malignancies.
Do not use if
No specific contraindications are listed, except known hypersensitivity to the product components.
Side effects
Common adverse effects include fatigue, decreased appetite, cough, rash, diarrhea, and infusion-related reactions.
Warnings
May cause severe or fatal immune-mediated reactions affecting lungs, liver, intestines, endocrine organs, and other tissues.
How it works
A PD-L1 blocking monoclonal antibody that enhances antitumor immune responses by restoring T-cell activity.
Storage
Store refrigerated at 2–8°C and protect from freezing.
